Abstract
Type 1 hepatorenal syndrome (HRS) can be a rapidly fatal consequence of liver failure. Recent studies have utilized vasoconstrictor therapies to combat splanchnic vasodilatation. We aimed to evaluate the efficacy of a promising treatment for type 1 HRS. We compared the survival of HRS patients who received octreotide and midodrine treatment at Rancho Los Amigos Medical Center with a concurrent untreated control group of HRS patients who did not receive this treatment. Of the 81 patients, 60 were treated with octreotide/midodrine and 21 were controls. Mortality was significantly lower in the treatment group (43%) than in the controls (71%; P < 0.05). Furthermore, 24 study patients (40%) had a sustained reduction of serum creatinine compared with only 2 controls (10%; P < 0.05). This large retrospective study suggests that octreotide/midodrine treatment appears to improve 30-day survival. A randomized, controlled trial is the next important step toward evaluating this treatment modality.
Similar content being viewed by others
References
v. Frerichs T (1877) Tratado práctico de las enfermedades del hígado, de los vasos hepáticos y de las vias biliares. Librería Extranjera y Nacional, científica y Literaria, Madrid, pp 362–353
Flint A (1863) Clinical report on hydro-peritoneum based on an analysis of forty-six cases. Am J Med Sci 45:306–339
Hecker R, Sherlock S (1956) Electrolyte and circulatory changes in terminal liver failure. Lancet 2:1221–1225
Arroyo V, Ginés P, Gerbes A, Dudley FJ, Gentillini P, Laffi G, Reynolds TB, Ring-Larsen H, Scholmerich J (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23:164–176
Ginés A, Escorsell A, Ginés P, Salo J, Jimenez W, Inglada L, Navasa M, Claria J, Rimola A, Arroyo V (1993) Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 105:229–236
Fernandez-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriguez-Eire JL, Garcia-Plaza A, Leal J (1989) Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 97:1304–1312
Arroyo V, Guevara M, Ginés P (2002) Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 122:1658–1676
Wong F, Blendis L (2001) New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 34:1242–1251
Gonwa TA, Morris CA, Goldstein RM, Husbert BS, Klintmalm GB (1991) Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 91:428–430
Gonwa TA, Klintmalm GB, Jennings LS, Goldstein RM, Husberg B (1995) Impact of pretransplant renal function on survival after liver transplantation. Transplantation 59:361–365
Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE (1973) Recovery from hepatorenal syndrome after orthotopic liver transplantation. N Engl J Med 289:1155–1159
Ortega R, Ginés P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jimenez W, Arroyo V, Rodes J (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36:941–948
Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122:923–930
Duhamel C, Mauillon J, Berkelmans I, Bourienne A, Tranvouez JL (2000) Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 95:2984–2985
Gulberg V, Bilzer M, Gerbes AL (1999) Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30:870–875
Angeli P, Volpin R, Gerunda G, Craighero R, Romero P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffel-Faccioli A, Gatta A (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29:1690–1697
Clive DM, Stoff JS (1984) Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563–572
Cárdenas A, Ginés P, Rodés J (2003) Renal complications. In: Schiff ER, Sorrell MF, Maddrey WC (eds) Schiff's diseases of the liver. 9th ed. Lippincott Williams & Wilkins, Philadelphia, pp 497–509
Dagher L, Patch D, Marley R, Moore K, Burroughs A (2000) Pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther 14:515–521
Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119:1637–1648
Wong F, Pantea L, Sniderman K (2004) Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40(1):55–64
Afessa B, Kublis PS (2000) Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction. Am J Gastroenterol 95:484–489
Navasa M, Rodes J (1997) Management of ascites in the patient with portal hypertension with emphasis on spontaneous bacterial peritonitis. Semin Gastrointest Dis 8:200–209
Papper S (1983) The hepatorenal syndrome. In: Epstein M (ed) The kidney in liver disease. 2nd ed. Elsevier Biomedical, New York, pp 87–106
Acknowledgment
This paper is dedicated to Dr. Telfer B. Reynolds, who spent his distinguished career studying, teaching about, and caring for patients with liver failure and fluid and electrolyte imbalance. His influence on the authors and on this study cannot be quantified.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Esrailian, E., Pantangco, E.R., Kyulo, N.L. et al. Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome. Dig Dis Sci 52, 742–748 (2007). https://doi.org/10.1007/s10620-006-9312-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9312-0